0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > IL-10

IL-10

Brief Information

Name:Interleukin-10
Target Synonym:Interleukin 10,IL-10,IL10,CSIF,Cytokine Synthesis Inhibitory Factor,T-Cell Growth Inhibitory Factor,Interleukin-10,GVHDS,IL10A,TGIF
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Phase 3 Clinical

Licensing

Project Name Modality Therapeutic Area Indications Stage Right Available
IL10 / IL10RA mAb Monospecific antibody Infectious and parasitic diseases Immunodeficiencies PCC Global

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

GMP-L10H25-Cell-based assay
 IL-10 CELL

GMP Human IL-10 Protein (Cat. No. GMP-L10H25) inhibits the secretion IL-6 by RAW264.7 cells. The specific activity of GMP Human IL-10 Protein is > 1.00 x 10^7 IU/mg, which is calibrated against WHO Reference Reagent Interleukin-10 (Human, rDNA derived) (NIBSC code: 93/722) (QC tested).

IL0-H5219-Cell-based assay
 IL-10 CELL

Human IL-10, premium grade (Cat. No. IL0-H5219) inhibits the secrection IL-6 by RAW264.7 cells. The specific activity of Human IL-10, premium grade is >1.00 x 10^7 IU/mg, which is calibrated against WHO Reference Reagent Interleukin-10 (Human, rDNA derived) (NIBSC code: 93/722) (QC tested).

IL0-H5219-ELISA
 IL-10 ELISA

Immobilized Human IL-10, premium grade (Cat. No. IL0-H5219) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-10 R alpha, Fc,Avitag (Cat. No. ILR-H82F6) with a linear range of 0.2-5 ng/mL (QC tested).

IL0-H5219-MALS-HPLC
IL-10 MALS images

The purity of Human IL-10, premium grade (Cat. No. IL0-H5219) is more than 90% and the molecular weight of this protein is around 35-45 kDa verified by SEC-MALS.

Customer Reviews

Synonym Name

CSIF,IL-10,IL10A,TGIF,B-TCGF,GVHDS,MGC126450,MGC126451,RP11-262N9.1,Interleukin-10

Background

Interleukin-10 (IL-10) is also known as human cytokine synthesis inhibitory factor (CSIF), is an anti-inflammatory cytokine. IL-10 is an immunosuppressive cytokine produced by a variety of mammalian cell types including macrophages, monocytes, T cells, B cells and keratinocytes. Mature human IL-10 shares 72% - 86% amino acid sequence identity with bovine, canine, equine, feline, mouse, ovine, porcine, and rat IL-10. Whereas human IL-10 is active on mouse cells, mouse IL-10 does not act on human cells. IL-10 is capable of inhibiting synthesis of pro-inflammatory cytokines such as IFN-γ, IL-2, IL-3, TNFα and GM-CSF made by cells such as macrophages and regulatory T-cells. It also displays a potent ability to suppress the antigen-presentation capacity of antigen presenting cells. However, it is also stimulatory towards certain T cells and mast cells and stimulates B cell maturation and antibody production. Knockout studies suggested the function of Interleukin-10 / IL-10 as an essential immunoregulator in the intestinal tract. Patients with Crohn's disease react favorably towards treatment with bacteria producing recombinant interleukin-10, showing the importance of interleukin-10 for counteracting excessive immunity in the human body.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Mesenchymal stem cells therapy (Therapeutic Solutions International) Phase 3 Clinical Jadi Cell LLC Coronavirus Disease 2019 (COVID-19) Details
KLS-2031 KLS-2031 Phase 2 Clinical Kolon Life Science. Inc Radiculopathy Details
WP-1303 (worgpharma) ATX-MS-1467; ATX-MS-01; M-2736; WP-1303; MSC-2358825A Phase 2 Clinical Apitope Technology Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Multiple Myeloma Details
XT-150 XT-101-R; XT-101; XT-150 Phase 2 Clinical Xalud Therapeutics Inc Multiple Sclerosis; Neuralgia; Back Pain; Osteoarthritis, Knee; Arthralgia; Inflammation; Osteoarthritis, Spine Details
Mesenchymal stem cells therapy (Therapeutic Solutions International) Phase 3 Clinical Jadi Cell LLC Coronavirus Disease 2019 (COVID-19) Details
KLS-2031 KLS-2031 Phase 2 Clinical Kolon Life Science. Inc Radiculopathy Details
WP-1303 (worgpharma) ATX-MS-1467; ATX-MS-01; M-2736; WP-1303; MSC-2358825A Phase 2 Clinical Apitope Technology Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Multiple Myeloma Details
XT-150 XT-101-R; XT-101; XT-150 Phase 2 Clinical Xalud Therapeutics Inc Multiple Sclerosis; Neuralgia; Back Pain; Osteoarthritis, Knee; Arthralgia; Inflammation; Osteoarthritis, Spine Details

This web search service is supported by Google Inc.

totop

Laisser un message